Osteopontin As a Biomarker for Osteosarcoma Therapy and Prognosis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Mar 12

PMID 30854034

Citations 33

Authors

Xingwen Han

Wenji Wang

Jingjing He

Lei Jiang

Xun Li

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common bone malignancy, and is particularly prevalent in children and adolescents. OS is an aggressive tumor with a tendency to metastasize and invade to para-carcinoma tissues. The primary treatment for this tumor is a combination of surgery and chemotherapy. However, the prognosis remains poor due to chemoresistance and early metastasis. Osteopontin (OPN), a multifunctional secreted protein, has emerged as an important potential biomarker for diagnosing and treating cancer. The overexpression of OPN has been found in numerous malignant tumors, including breast, lung, gastric and ovarian cancer, as well as melanoma. Recent studies have suggested that OPN may provide an important function in the diagnosis and treatment of OS. The present review summarizes current knowledge and progress in understanding the potential role of OPN as a biomarker in OS.

Citing Articles

The Role of Epithelial-Mesenchymal Transition in Osteosarcoma Progression: From Biology to Therapy.

Patrascu A, Tarca E, Lozneanu L, Ungureanu C, Morosan E, Parteni D Diagnostics (Basel). 2025; 15(5).

PMID: 40075892 PMC: 11898898. DOI: 10.3390/diagnostics15050644.

Integrins identified as potential prognostic markers in osteosarcoma through multi-omics and multi-dataset analysis.

Cui L, Zhao S, Teng H, Yang B, Liu Q, Qin A NPJ Precis Oncol. 2025; 9(1):19.

PMID: 39825088 PMC: 11742673. DOI: 10.1038/s41698-024-00794-5.

Neural repair function of osteopontin in stroke and stroke‑related diseases (Review).

Sun X, Li C Exp Ther Med. 2024; 28(6):459.

PMID: 39478739 PMC: 11523235. DOI: 10.3892/etm.2024.12749.

Pediatric cancer-pathology and microenvironment influence: a perspective into osteosarcoma and non-osteogenic mesenchymal malignant neoplasms.

Sergi C Discov Oncol. 2024; 15(1):358.

PMID: 39154307 PMC: 11330953. DOI: 10.1007/s12672-024-01240-5.

Serum Osteopontin as a Potential Marker for Metastasis and Prognosis in Primary Osteogenic Sarcoma: A Systematic Review.

Agrawal A, Saini D, Nanda R Cureus. 2024; 16(5):e60544.

PMID: 38887353 PMC: 11181102. DOI: 10.7759/cureus.60544.

References

Liu S, Hu G, Liu Y, Liu S, Gao H, Zhang C . Effect of human osteopontin on proliferation, transmigration and expression of MMP-2 and MMP-9 in osteosarcoma cells. Chin Med J (Engl). 2004; 117(2):235-40. View

Terashi T, Aishima S, Taguchi K, Asayama Y, Sugimachi K, Matsuura S . Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int. 2004; 24(1):38-45. DOI: 10.1111/j.1478-3231.2004.00886.x. View

Senger D, Wirth D, Hynes R . Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979; 16(4):885-93. DOI: 10.1016/0092-8674(79)90103-x. View

Kai K, Dittmar R, Sen S . Secretory microRNAs as biomarkers of cancer. Semin Cell Dev Biol. 2017; 78:22-36. DOI: 10.1016/j.semcdb.2017.12.011. View

Ferrari S, Serra M . An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015; 16(18):2727-36. DOI: 10.1517/14656566.2015.1102226. View

Leung D, Lim P, Cheung T, Wong R, Yim S, Ng M . Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients. PLoS One. 2016; 11(8):e0160412. PMC: 4975440. DOI: 10.1371/journal.pone.0160412. View

Zduniak K, Agrawal A, Agrawal S, Hossain M, Ziolkowski P, Weber G . Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer. 2016; 16:441. PMC: 4940753. DOI: 10.1186/s12885-016-2484-x. View

Allen J, Moore M . Environmental prognostics: is the current use of biomarkers appropriate for environmental risk evaluation?. Mar Environ Res. 2004; 58(2-5):227-32. DOI: 10.1016/j.marenvres.2004.03.119. View

Simpson S, Dunning M, de Brot S, Grau-Roma L, Mongan N, Rutland C . Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 2017; 59(1):71. PMC: 5655853. DOI: 10.1186/s13028-017-0341-9. View

10.

Zivny J, Leahomschi S, Klener Jr P, Zivny J, Haluzik M, Cibula D . Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma. Folia Biol (Praha). 2017; 62(6):258-262. DOI: 10.14712/fb2016062060258. View

11.

Boldrini L, Donati V, DellOmodarme M, Prati M, Faviana P, Camacci T . Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 2005; 93(4):453-7. PMC: 2361587. DOI: 10.1038/sj.bjc.6602715. View

12.

Wu I, Wu M, Chou S, Yang S, Goan Y, Lee J . Osteopontin expression in squamous cell cancer of the esophagus. World J Surg. 2008; 32(9):1989-95. DOI: 10.1007/s00268-008-9609-6. View

13.

Forootan S, Foster C, Aachi V, Adamson J, Smith P, Lin K . Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2005; 118(9):2255-61. DOI: 10.1002/ijc.21619. View

14.

Selmic L, Burton J, Thamm D, Withrow S, Lana S . Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 2014; 28(2):554-63. PMC: 4857984. DOI: 10.1111/jvim.12313. View

15.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G . Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32(6):423-36. DOI: 10.1016/j.ctrv.2006.05.005. View

16.

Liu S, Zhang D, Sui X, Zhang L, Cai Z, Sun L . The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA. Cell Mol Biol Lett. 2007; 13(1):11-9. PMC: 6275891. DOI: 10.2478/s11658-007-0031-0. View

17.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M . CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014; 14(3):342-56. DOI: 10.1016/j.stem.2014.01.009. View

18.

Reddy K, Wafa H, Gaston C, Grimer R, Abudu A, Jeys L . Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?. Bone Joint J. 2015; 97-B(1):115-20. DOI: 10.1302/0301-620X.97B1.33924. View

19.

Mortus J, Zhang Y, Hughes D . Developmental pathways hijacked by osteosarcoma. Adv Exp Med Biol. 2014; 804:93-118. DOI: 10.1007/978-3-319-04843-7_5. View

20.

Anborgh P, Caria L, Chambers A, Tuck A, Stitt L, Brackstone M . Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res. 2015; 7(4):723-32. PMC: 4455347. View